EducationalSymposia
Description
Room: 112 (P1)
INDICATION-BASED PRICING; WHO WINS, WHO LOSES, AND WHERE NEXT?
This symposium will explore current literature and perspectives on the rationale for indication-based pricing (IBP). The presenters will propose fundamental questions to consider as the implementation of IBP advances. Attendees will participate in an exercise and will be asked to come to consensus on what models should be pursued for its implementation.

Moderator: Paul Naish, MA Cantab
Director, Oncology Advocacy & Government Affairs, AstraZeneca, Cambridge, UK

Speaker: Adrian Towse, MA, MPhil
Director, Office of Health Economics, London, UK

Speaker: Greg Rossi, PhD
Vice President: Global Medicines Leader (Lynparza), AstraZeneca, Cambridge, UK

Speaker: Francis Arickx, Pharmacist
Head of the Directorate Reimbursement of Medicines and Pharmaceutical Policy, Health Care Department, National Institute for Health and Disability Insurance RIZIV INAMI, Brussels, Belgium

(Sponsored by AstraZeneca)